uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE silencing technology.
|
Free QURE Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.43 out of 4) 53rd percentile
(ranked higher than approx. 53% of all stocks covered)
Analysts' Target Price: QURE Stock Forecast Based on Zacks ABR data; powered by Xignite |